potential COVID-19 treatments - versus control - for COVID-19 mild to moderate pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

death D28 0.62 [0.46, 0.82]< 10%12 studies (12/-)99.9 %highlow lowcrucial-
death or transfer to ICU 0.89 [0.59, 1.34]< 146%2 studies (2/-)71.8 %highnot evaluable lowcrucial-
deaths 0.75 [0.64, 0.88]< 10%34 studies (34/-)100.0 %highcritical lowcrucial-
deaths (time to event analysis only) 0.68 [0.43, 1.08]< 10%4 studies (4/-)95.0 %some concernnot evaluable moderatecrucial-
clinical deterioration 0.69 [0.52, 0.92]< 149%16 studies (16/-)99.4 %highlow lowimportant-
clinical improvement 1.24 [1.04, 1.47]> 140%15 studies (15/-)99.3 %highlow lowimportant-
clinical improvement (14-day) 1.17 [0.93, 1.47]> 135%9 studies (9/-)91.6 %some concernnot evaluable moderateimportant-
clinical improvement (21-day) 2.09 [0.04, 119.96]> 10%1 study (1/-)63.7 %some concernnot evaluable moderateimportant-
clinical improvement (28-day) 1.34 [1.10, 1.62]> 146%5 studies (5/-)99.8 %some concernserious moderateimportant-
clinical improvement (7-day) 1.24 [0.99, 1.55]> 165%10 studies (10/-)96.7 %highcritical lowimportant-
clinical improvement (time to event analysis only) 1.25 [1.05, 1.48]> 148%8 studies (8/-)99.5 %highnot evaluable lowimportant-
death or ventilation 0.75 [0.63, 0.88]< 10%5 studies (5/-)100.0 %some concernnot evaluable moderateimportant-
hospital discharge 1.29 [0.96, 1.73]> 151%6 studies (6/-)95.5 %highnot evaluable lowimportant-
hospitalization 1.00 [0.14, 7.34]< 10%1 study (1/-)50.0 %some concernnot evaluable moderateimportant-
mechanical ventilation 0.88 [0.59, 1.32]< 116%13 studies (13/-)72.7 %highcritical lowimportant-
mechanical ventilation (time to event analysis only) 0.06 [0.01, 0.83]< 10%1 study (1/-)98.2 %some concernnot evaluable moderateimportant-
radiologic improvement (14-day) 1.82 [0.95, 3.51]> 139%4 studies (4/-)96.4 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 0.40 [0.02, 6.97]> 177%3 studies (3/-)26.9 %highnot evaluable lowimportant-
viral clearance 1.41 [1.07, 1.86]> 167%15 studies (15/-)99.2 %highcritical lowimportant-
viral clearance (time to event analysis only) 1.12 [0.82, 1.54]> 162%5 studies (5/-)77.1 %highnot evaluable lowimportant-
viral clearance by day 14 0.98 [0.18, 5.42]> 194%9 studies (9/-)49.0 %highnot evaluable lowimportant-
viral clearance by day 7 1.28 [1.01, 1.63]> 168%13 studies (13/-)97.8 %highlow lowimportant-
ICU admission 0.94 [0.68, 1.30]< 10%7 studies (7/-)63.9 %highnot evaluable lownon important-
recovery 1.13 [0.98, 1.31]> 10%3 studies (3/-)95.4 %some concernnot evaluable moderatenon important-

safety endpoints 00

serious adverse events 0.74 [0.53, 1.04]< 10%15 studies (15/-)96.0 %highcritical lowimportant-
acute kidney injury 1.18 [0.44, 3.18]< 10%1 study (1/-)37.2 %some concernnot evaluable moderatenon important-
adverse events 1.89 [1.36, 2.61]< 167%18 studies (18/-)0.0 %highlow lownon important-
arrhythmia 2.24 [0.23, 21.69]< 10%1 study (1/-)24.5 %some concernnot evaluable moderatenon important-
elevated liver enzymes